Chemical exposure, ras oncogene activation, and acute myeloid leukemia.
نویسندگان
چکیده
Interest in the association between mutations in the ras family of oncogenes and acute myeloid leukemia (AML) began with the description of a point mutation in N-ras (also known as NRAS) in a patient with AML (/). Since then, clinical reports suggest that 15%-30% of patients with AML exhibit ras oncogene activation, making it the single most common genetic perturbation in AML (2,3). The vast majority of these mutations occur in N-ras. Occasionally, K-ras (also known as KRAS2) mutations are found. Mutations in H-ras (also known as HRAS) are very rarely demonstrated (2,3). The role of ras oncogene activation in AML patients remains unclear and can occur either early or late in the development of the disease (2-4). Mutation in ras oncogenes probably represents one of many genetic events that occur in leukemia. This mutation, however, could be especially important in the early stages of leukemia development, because it may cause chromosomal instability and increase the probability of other genetic alterations (5,6). If ras mutations had no functional role in leukemia development, they would occur randomly and at similar frequencies in different leukemias. This situation is not the case. Although the incidence of these mutations in AML patients is 15%-30%, in patients with acute lymphocytic leukemia, it is lower—only 10%-18%. In patients with chronic myeloid leukemia, the incidence is less than 5%, and in those with chronic lymphocytic leukemia, it is 0% (3). The highest incidence of ras mutations occurs in patients with the myelodysplasia subtype of chronic myelomonocytic leukemia, where 68% of patients carry a mutation (3). Thus, such mutations may be particularly important in specific subcategories of the leukemias and less important or unimportant in others. To clarify relationships between specific exposures and disease occurrence in an epidemiological sense, it is important to classify disease outcomes into subgroups that are as homogeneous as possible. In this manner, exposure associations confined to a specific subtype can be clearly identified. In this issue of the Journal, Taylor and his coworkers (7) argue that, since AML appears to be a heterogeneous disease at the molecular and cytogenetic levels, it is possible that certain environmental agents might be linked to specific molecular subtypes. Using ras mutationpositive (ras-positive) AML as a molecular subtype, they go on to show that this form of leukemia is strongly associated with employment in any of 32 a priori occupations reported to be associated with increased leukemia risk (7). Patients with ras-positive AML had a significantly higher frequency of working 5 or more years in an a priori high-risk occupation than did population-based control subjects (odds ratio [OR] = 5.9). Furthermore, ras-positive AML patients were more likely than control subjects to have had dermal exposure (OR = 4.5) or to have breathed chemical vapors on the job (OR = 3.0), associations which became stronger after exposure status was reclassified on the basis of use of protective equipment. Similar results were obtained when exposure patterns among ras-positive and ras mutationnegative (ras-negative) patients were compared. Earlier studies (8-11) had shown a link between chemical exposures and cytogenetically characterized subtypes of AML, e.g., association of alkylating agents used in chemotherapy with aberrations in the -5/-5q and -7/-7q chromosomal regions; association of occupational exposure with these aberrations plus aberrations in t(8;21) and trisomy 8; and association of smoking with aberrations in +8 and inv(16). The study by Taylor et al. (7) is the first, however, to use mutations in a proto-oncogene, which lead to activation of the oncogene, to subclassify leukemia and relate the subtype of AML characterized by ras mutation activation with employment in an occupation associated with elevated leukemia occurrence and substantial chemical exposure. In an important paper in the American Journal of Epidemiology in 1989 (12), Taylor suggested that oncogene assays could become a powerful epidemiological tool for investigating tumor etiology. His group's article in this issue further advances that concept. It is interesting to note that the occupational associations observed in this study would not have been detected had ras-positive and ras-negative patients been analyzed as a single group. This observation suggests that the leukemogenic potential of some previously studied occupations and chemical exposures may have been underestimated. Moreover, ras mutations tend to be chemical specific (13,14); thus, a larger study of ras-positive leukemias may enable identification of associations between specific ras mutations and particular chemical exposures. Application of molecular genetics may, therefore, significantly enhance the potential for epidemiological studies to
منابع مشابه
Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents.
Mutations of the N- and K-ras genes occur in approximately 15-30% of acute myeloid leukaemia patients. The role of the oncogenic ras in leukaemogenesis remains unclear. Few studies have revealed that mutations in the ras oncogene family are more probably found in acute myeloid leukaemia patients with previous exposure to toxic agents. A case-case study was conducted in the areas of Florence and...
متن کاملOncogene Activation in Human Myeloid Leukemia1
We have studied by means of DMA-mediated gene transfer the activation of protooncogenes in human myeloid leukemias that represent various stages of myeloid differentiation. DMA from three cell lines, HL-60 (promyelocytic leukemia), Rc2a (myelomonocytic leukemia), and KG-1 (acute myeloblastic leukemia), was capable of transforming NIH/3T3 cells. Hybridization analy sis indicated that, in all thr...
متن کاملMLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.
A rare location, t(6;11)(q27;q23) (MLL-AF6), is associated with poor outcome in childhood acute myeloid leukemia (AML). The described mechanism by which MLL-AF6, through constitutive self-association and in cooperation with DOT-1L, activates aberrant gene expression does not explain the biological differences existing between t(6;11)-rearranged and other MLL-positive patients nor their differen...
متن کاملHigh frequency of N-ras activation in acute myelogenous leukemia.
Using the NIH/3T3 cell transfection assay, activated cellular oncogenes have been detected in around 10% to 20% of human tumors. From a series of DNA preparations from tissues infiltrated with acute myelogenous leukemia (AML), 50% (3/6) caused transformation of NIH/3T3 cells. Thus AML appears to be the human tumor with the highest frequency of oncogenes detected by DNA transfection. In each cas...
متن کاملStatins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Interactions between UCN-01 and HMG-CoA reductase inhibitors (ie, statins) have been examined in human leukemia and myeloma cells. Exposure of U937 and U266 cells to minimally toxic concentrations of UCN-01 and various statins (eg, lovastatin, simvastatin, or fluvastatin) dramatically increased mitochondrial dysfunction, caspase activation, and apoptosis. Comparable effects were observed in oth...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the National Cancer Institute
دوره 84 21 شماره
صفحات -
تاریخ انتشار 1992